NCT07271667Phase 2Recruiting

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

Study sponsor: Curis, Inc. · CRIS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-11Estimated
Enrollment · participants108Estimated
Source updated2026-06-12Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source